ArticleCellular & molecular immunology2024

The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.

Fan Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.